The Institutional Review Board Has Approved the Increase in Number of Patients from Sixty (60) to Ninety (90). The Company to Expand the Study into Additional Trial Sites in Europe.
The Institutional Review Board Has Approved the Increase in Number of Patients from Sixty (60) to Ninety (90). The Company to Expand the Study into Additional Trial Sites in Europe.